IP Library Granted Patent US 11,021,580
Granted Patent B2
US 11,021,580 · App. 15/747,648 · Granted Jun 1, 2021

Process for efficient cross-linking of hyaluronic acid

Inventor: Morgan Karlsson (Knivsta, SE)
Assignee: Galderma Holding SA
C08J3/24A61K8/735A61K9/06A61K31/728A61K47/36A61L27/20A61Q19/08C08B37/0072C08J3/075C08L5/08A61K2800/91A61L2430/34C08J2305/08C08L2201/54C08L2203/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,021,580
App. No.
15/747,648
Granted
Jun 1, 2021
Kind
B2
Abstract

A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.

Claims (15)

1. A process for manufacturing a cross-linked hyaluronic acid (HA) gel product, the process comprising:

(a) obtaining an aqueous mixture of HA and a diepoxide cross-linking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane, wherein the HA is dissolved in an aqueous solution comprising 6-8% (w/w) inorganic hydroxide, and wherein the dissolved HA constitutes 33-35% (w/w) of the aqueous mixture; and

(b) cross-linking the aqueous mixture at 10-75° C. to obtain the cross-linked HA gel product, wherein the HA is cross-linked in a single step.

2. The process according to claim 1 , wherein the aqueous solution of (a) comprises 6% (w/w) inorganic hydroxide.

3. The process according to claim 1 , wherein the aqueous solution of (a) comprises 8% (w/w) inorganic hydroxide.

4. The process according to claim 1 , wherein the aqueous mixture of (a) comprises 33% (w/w) HA.

5. The process according to claim 1 , wherein the aqueous mixture of (a) comprises 35% (w/w) HA.

6. The process according to claim 1 , wherein the cross-linking occurs at room temperature.

7. The process according to claim 1 , wherein the cross-linking is performed for 4-36 h.

8. The process according to claim 1 , wherein the cross-linking agent is 1,4-butanediol diglycidyl ether (BDDE).

9. The process according to claim 1 , further comprising (c) isolating the cross-linked HA product.

10. The process according to claim 9 , wherein the isolating comprises precipitating the HA gel product.

11. The process according to claim 1 , wherein the cross-linking is performed at 15-35° C. for 2-40 h so as to obtain the cross-linked HA gel product.

12. The process according to claim 1 , wherein the cross-linking is performed at 15-35° C.

13. The process according to claim 1 , wherein the cross-linked HA gel product exhibits an elastic modulus of at least 450 Pa.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2024
From: OHRLUND, AKE
To: GALDERMA HOLDING SA
Reel/Frame 066715/0198 →
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Apr 30, 2021
From: NESTLÉ SKIN HEALTH SA
To: GALDERMA HOLDING SA
Reel/Frame 056101/0498 →
ASSET TRANSFER AGREEMENT Recorded Apr 30, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH SA
Reel/Frame 056106/0098 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER PREVIOUSLY RECORDED AT REEL: 048919 FRAME: 0141. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 25, 2019
From: KARLSSON, MORGAN
To: GALDERMA S.A
Reel/Frame 048999/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2019
From: KARLSSON, MORGAN
To: GALDERMA S.A
Reel/Frame 048919/0141 →